Clin Liver Dis. 2009 Aug;13(3):391-401.

Hepatitis C virus infection and immunomodulatory therapies.

Source

Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Abstract

Hepatitis C virus (HCV) infection remains a large-scale and significant health concern. The combination of subcutaneously administered pegylated interferon and oral ribavirin is the FDA-approved regimen for the treatment of chronic HCV infection. Combination therapy may result in a sustained virologic response leading to HCV eradication, with a reduction in risk for cirrhosis, hepatic decompensation, and hepatocellular carcinoma. However, the combination of PEG-IFN and ribavirin does not universally result in cure in all patients who undergo treatment. In this article, the authors discuss immunomodulatory therapies and clinical trials in the treatment of HCV infection.

PMID:: 19628156; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Molecular Biology Databases

RIBAVIRIN - HSDB

Supplemental Content

Save items

Related citations in PubMed

Review The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. [Cell Immunol. 2010]
Review The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus.
Salem ML, El-Demellawy M, El-Azm AR. Cell Immunol. 2010; 262(2):96-104. Epub 2010 Mar 6.
[Treatment of chronic viral hepatitis]. [Ugeskr Laeger. 2008]
[Treatment of chronic viral hepatitis].
Pedersen C, Pedersen CR. Ugeskr Laeger. 2008 Jun 9; 170(24):2137-40.
Review [Antiviral treatment of hepatitis C virus infection]. [Rev Med Interne. 1999]
Review [Antiviral treatment of hepatitis C virus infection].
Silvain C. Rev Med Interne. 1999 Aug; 20 Suppl 3:331s-340s.
Review Old and emerging therapies in chronic hepatitis C: an update. [J Viral Hepat. 2008]
Review Old and emerging therapies in chronic hepatitis C: an update.
Deutsch M, Hadziyannis SJ. J Viral Hepat. 2008 Jan; 15(1):2-11.
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. [J Viral Hepat. 2009]
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, et al. J Viral Hepat. 2009 Aug; 16(8):578-85. Epub 2009 Jun 22.

See reviews... See all...

Cited by 2 PubMed Central articles

Current status and future directions in the management of chronic hepatitis C. [Virol J. 2012]
Current status and future directions in the management of chronic hepatitis C.
Aman W, Mousa S, Shiha G, Mousa SA. Virol J. 2012 Mar 2; 9:57. Epub 2012 Mar 2.
Review Viral exploitation of host SOCS protein functions. [J Virol. 2011]
Review Viral exploitation of host SOCS protein functions.
Akhtar LN, Benveniste EN. J Virol. 2011 Mar; 85(5):1912-21. Epub 2010 Nov 17.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Hepatitis C virus infection and immunomodulatory therapies.
Hepatitis C virus infection and immunomodulatory therapies.
Clin Liver Dis. 2009 Aug ;13(3):391-401.

PubMed
Trends in hospitalizations for adults with congenital heart disease in the U.S.
Trends in hospitalizations for adults with congenital heart disease in the U.S.
J Am Coll Cardiol. 2009 Jul 28 ;54(5):460-7.

PubMed
Chia seed does not promote weight loss or alter disease risk factors in overweig...
Chia seed does not promote weight loss or alter disease risk factors in overweight adults.
Nutr Res. 2009 Jun ;29(6):414-8.

PubMed
Time-divided ingestion pattern of casein-based protein supplement stimulates an ...
Time-divided ingestion pattern of casein-based protein supplement stimulates an increase in fat-free body mass during resistance training in young untrained men.
Nutr Res. 2009 Jun ;29(6):405-13.

PubMed
Consumption of the slow-digesting waxy maize starch leads to blunted plasma gluc...
Consumption of the slow-digesting waxy maize starch leads to blunted plasma glucose and insulin response but does not influence energy expenditure or appetite in humans.
Nutr Res. 2009 Jun ;29(6):383-90.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Hepatitis C virus infection and immunomodulatory therapies.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 2 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information